Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI

View Full Paper
Ask AI
Bookmark
Share

Authors

SKShinya KimuraMSMasashi SawaYSYoshio Saburi

Discussion

Loading...

Member takes

Overview

Multi-institutional analysis shows sustained treatment-free remission in chronic myeloid leukemia, highlighting potential for treatment discontinuation within clinical practice.

Key Points

  • Overall treatment-free remission rate reached 65.2% at 60 months, suggesting favorable long-term outcomes for patients who stopped tyrosine kinase inhibitors.
  • Multivariate analysis determined longer duration of deep molecular response as a critical predictor for treatment-free remission success in chronic myeloid leukemia.
  • Observational analysis documented outcomes from both prospective and retrospective cohorts, with detailed patient follow-up from September 2019 to March 2025.
  • Findings support continuation of treatment discontinuation strategies in clinical practice, although further validation is needed for second treatment-free remission attempts.

Cite This Study

Kimura et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e413https://doi.org/10.1182/blood-2025-5545
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response2025
  2. 2Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors2025
  3. 3Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia2026
  4. 4TKI Use and Treatment-Free Remission in Chronic Myeloid Leukemia: Evidence from a Regional Cohort Study in the Canary Islands2025
  5. 5Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.2025